- Trials with a EudraCT protocol (35)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (1)
35 result(s) found for: Turns.
Displaying page 1 of 2.
EudraCT Number: 2009-013054-33 | Sponsor Protocol Number: V72P6E1 | Start Date*: 2009-08-18 |
Sponsor Name:Novartis Vaccines and Diagnostics Srl. | ||
Full Title: A Phase 2, Open-Label, Single-Center, Extension Study Evaluating Antibody Persistence compared to Naïve Children and Safety, Tolerability and Immunogenicity of Booster Doses of Novartis rMenB±OMV N... | ||
Medical condition: The Novartis Meningococcal B recombinant vaccine is intended for prevention of meningitis and/or septicemia caused by Neisseria meningitidis serogroup B. The objective of the Novartis Meningococcal... | ||
Disease: | ||
Population Age: Children, Under 18 | Gender: Male, Female | |
Trial protocol: GB (Completed) | ||
Trial results: View results |
EudraCT Number: 2009-013075-21 | Sponsor Protocol Number: V72P9E1 | Start Date*: 2009-08-18 |
Sponsor Name:Novartis Vaccines and Diagnostics Srl. | ||
Full Title: A Phase 2, Open-Label, Single-Center, Extension Study Evaluating Antibody Persistence compared to Naïve Children and Safety, Tolerability and Immunogenicity of a Booster Dose of Novartis rMenB±OMV ... | ||
Medical condition: The Novartis Meningococcal B recombinant vaccine is intended for prevention of meningitis and/or septicemia caused by Neisseria meningitidis serogroup B. The objective of the Novartis Meningococcal... | ||
Disease: | ||
Population Age: Children, Under 18 | Gender: Male, Female | |
Trial protocol: GB (Completed) | ||
Trial results: View results |
EudraCT Number: 2015-001540-10 | Sponsor Protocol Number: 444563/024 | Start Date*: 2015-06-11 |
Sponsor Name:GlaxoSmithKline Biologicals | ||
Full Title: A phase III, double-blind, randomised, placebo-controlled, multi-country and multi-center study to assess the efficacy, immunogenicity and safety of two doses of GSK Biologicals’ oral live attenuat... | ||
Medical condition: Rotavirus gastroenteritis | ||
Disease: | ||
Population Age: Infants and toddlers, Under 18 | Gender: Male, Female | |
Trial protocol: Outside EU/EEA | ||
Trial results: View results |
EudraCT Number: 2014-004992-21 | Sponsor Protocol Number: V72P10E1 | Start Date*: 2014-11-28 |
Sponsor Name:Novartis Vaccines and Diagnostics S.r.l | ||
Full Title: A Phase 2b/3, Multi-Center, Extension Study of V72P10 to Assess Antibody Persistence at Eighteen Months After the Completion of the Vaccination Course in Study V72P10. | ||
Medical condition: Prophylaxis against invasive meningococcal disease | ||
Disease: | ||
Population Age: Adolescents, Under 18 | Gender: Male, Female | |
Trial protocol: Outside EU/EEA | ||
Trial results: View results |
EudraCT Number: 2007-000260-24 | Sponsor Protocol Number: NAC600-ZI-L-01-06 | Start Date*: 2007-05-21 | |||||||||||
Sponsor Name:ZAMBON ITALIA | |||||||||||||
Full Title: EVALUATION OF THE CLINICAL AND MICROBIOLOGICAL EFFICACY OF N-ACETILCISTEINA 600 MG, IN COMBINATION TO CEFPODOXIMA PROXETILE, IN THE THERAPY OF THE INFECTIONS OF THE HIGH RESPIRATORY WAYS IN ADULT P... | |||||||||||||
Medical condition: Infection of the high respiratory ways in adult patients | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2012-000657-30 | Sponsor Protocol Number: V72_28E1 | Start Date*: 2013-05-30 | |||||||||||
Sponsor Name:Novartis Vaccines and Diagnostics s.r.l. | |||||||||||||
Full Title: A Phase IIIB, Open Label, Multi-Center Extension Study of V72_28 to assess antibody persistence, and the safety and tolerability of a booster dose after the completion of the vaccination course in ... | |||||||||||||
Medical condition: A phase IIIB, Open Label, Multi Center extension study of V72_28 to assess antibody persistence, and the safety and tolerability of a booster dose after the completion of the vaccination course in ... | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: HU (Completed) ES (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2010-021528-81 | Sponsor Protocol Number: V72_28 | Start Date*: 2011-03-18 | |||||||||||
Sponsor Name:Novartis Vaccines and Diagnostics s.r.l. | |||||||||||||
Full Title: A Phase 3B, Open Label, Multi-Center Study to Evaluate the Safety, Tolerability and Immunogenicity of Novartis Meningococcal B Recombinant Vaccine When Administered Alone to Healthy Infants Accordi... | |||||||||||||
Medical condition: Estudio fase 3B, abierto y multicéntrico para evaluar la seguridad, tolerabilidad e inmunogenicidad de la vacuna meningocócica recombinante B de Novartis cuando se administra sola a bebés sanos seg... | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Children, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Completed) HU (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2014-002984-14 | Sponsor Protocol Number: AC-064A201 | Start Date*: 2015-06-05 |
Sponsor Name:ACTELION Pharmaceuticals Ltd | ||
Full Title: A multicenter, randomized, double-blind, placebo-controlled, dose-response study to investigate the biological activity, safety, tolerability, and pharmacokinetics of ACT-334441 in subjects with sy... | ||
Medical condition: Systemic lupus erythematosus | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: BG (Completed) | ||
Trial results: View results |
EudraCT Number: 2014-000057-37 | Sponsor Protocol Number: ABBA-2014 | Start Date*: 2014-04-30 |
Sponsor Name:University Medical Centre Utrecht | ||
Full Title: A B2-agonist as a CFTR activator in CF | ||
Medical condition: Cystic Fibrosis | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: NL (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2020-000993-27 | Sponsor Protocol Number: 2019PI115 | Start Date*: 2020-07-16 | |||||||||||
Sponsor Name:CHRU NANCY | |||||||||||||
Full Title: AGATA: Value of contrast-enhanced ultrasound in adnexal torsion | |||||||||||||
Medical condition: Adnexal torsion | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Female | ||||||||||||
Trial protocol: FR (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2011-004266-15 | Sponsor Protocol Number: ARYHM-1 | Start Date*: 2012-01-18 | |||||||||||
Sponsor Name:RMC, Skåne University Hospital | |||||||||||||
Full Title: Androgen replacement in young hypogonadal men: a 2 year randomized, double-blind placebo controlled study | |||||||||||||
Medical condition: Target population: Male hypogonadism (testosterone deficiency) As end points Bone mineralisation Body composition Markers of insulin sensitivity and cardiovascular disease Lipid profile H... | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male | ||||||||||||
Trial protocol: SE (Ongoing) NO (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2018-001678-10 | Sponsor Protocol Number: NL65853.029.18 | Start Date*: 2019-06-06 |
Sponsor Name:VU Medical Center | ||
Full Title: Tofacitinib: salvage therapy for patients with RCDII - a pilot study | ||
Medical condition: Refractory celiac disease type II | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: NL (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2010-019519-39 | Sponsor Protocol Number: RAPIT | Start Date*: 2012-03-14 |
Sponsor Name:Erasmus MC - Department of Neurology | ||
Full Title: Efficacy of RAD001/everolimus in Autism and NeuroPsychological deficits in children with TSC (RAPIT-trial) | ||
Medical condition: Tuberous Sclerosis Complex | ||
Disease: | ||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | |
Trial protocol: NL (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2014-000178-20 | Sponsor Protocol Number: MCT8-2014-1 | Start Date*: 2015-08-12 |
Sponsor Name:Erasmus Medical Centre | ||
Full Title: Thyroid hormone analog therapy of patients with severe psychomotor retardation caused by mutations in the MCT8 thyroid hormone transporter: The Triac Trial. | ||
Medical condition: This therapuetical trial will be conducted in patient with the Allan-Herndon-Dudley Syndrome (AHDS), casued by mutations in the thyroid hormone transporter MCT8. This results in the characteristic ... | ||
Disease: | ||
Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults | Gender: Male | |
Trial protocol: BE (Completed) CZ (Completed) DE (Completed) IT (Completed) FR (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2013-001969-16 | Sponsor Protocol Number: GS-US-183-0160 | Start Date*: 2013-10-21 | |||||||||||
Sponsor Name:Gilead Sciences, Inc. | |||||||||||||
Full Title: A Phase 2/3 Multicenter, Open-Label, Multicohort, Two-Part Study Evaluating the Pharmacokinetics (PK), Safety, and Antiviral Activity of Elvitegravir (EVG) Administered with a Background Regimen (B... | |||||||||||||
Medical condition: Human Immunodeficiency Virus (HIV-1) Infections | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Prematurely Ended) DE (Completed) ES (Completed) Outside EU/EEA | |||||||||||||
Trial results: View results |
EudraCT Number: 2015-000313-40 | Sponsor Protocol Number: GS-US-236-0112 | Start Date*: 2015-01-29 | |||||||||||
Sponsor Name:Gilead Sciences, Inc. | |||||||||||||
Full Title: A Phase 2/3, Open-Label Study of the Pharmacokinetics, Safety, and Antiviral Activity of the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate Single Tablet Regimen (STR) in HIV-1... | |||||||||||||
Medical condition: Human Immunodeficiency Virus, Type 1 (HIV-1) Infection | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: Outside EU/EEA | |||||||||||||
Trial results: View results |
EudraCT Number: 2011-004931-30 | Sponsor Protocol Number: V72P12E2 | Start Date*: 2012-10-10 |
Sponsor Name:Novartis Vaccines and Diagnostics S.r.l. | ||
Full Title: A Phase 3, Open Label, Multi-Center, Extension Study to Assess Antibody Persistence and Response to a Third or Fift Dose of Novartis Meningococcal B Recombinant Vaccine in 4-Year-Old Children Who ... | ||
Medical condition: Prevention of meningococcal disease caused by serogroup B Neisseria meningitidis by evaluating the Antibody persistence in 4-year old healthy children who previously received the Novartis meningoco... | ||
Disease: | ||
Population Age: Children, Under 18 | Gender: Male, Female | |
Trial protocol: GB (Completed) ES (Completed) IT (Completed) CZ (Completed) | ||
Trial results: View results |
EudraCT Number: 2014-003466-25 | Sponsor Protocol Number: 13.024 | Start Date*: 2014-12-18 | |||||||||||
Sponsor Name:Anders Gadegaard Jensen,Anesthesia and Intensive Care Unit, Odense University Hospital | |||||||||||||
Full Title: Randomized, double-blind, prospective, placebo-controlled trial of the effect of intravenous lidocaine infusion for postoperative pain management and bowel function in robot assisted laparoscopic c... | |||||||||||||
Medical condition: Postoperative pain after colon rectal cancer surgery are mainly intended to relieve as well resting as activity-induced pain. Secondarily, the choice of pain management should take into considerati... | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DK (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-005730-15 | Sponsor Protocol Number: GO-TEST-FINALE | Start Date*: 2021-01-26 | |||||||||||
Sponsor Name:Sint Maartenskliniek | |||||||||||||
Full Title: GOut TrEatment STrategy (GO TEST) FINALE study, a multicentre pragmatic randomized superiority trial of continuation versus cessation of urate lowering therapies in gout in remission. | |||||||||||||
Medical condition: Gout, arthritis urica | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2021-002612-31 | Sponsor Protocol Number: MANTICO | Start Date*: 2021-05-25 | |||||||||||
Sponsor Name:AZIENDA OSPEDALIERA UNIVERSITARIA INTEGRATA VERONA | |||||||||||||
Full Title: Adaptive, randomized, placebo-controlled trial to evaluate the efficacy of monoclonal antibodies in outpatients with mild or moderate COVID-19 (MANTICO) | |||||||||||||
Medical condition: COVID-19 | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
